Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV Tegileridine vs Hydromorphone for PONV After Laparoscopic Abdominal Surgery
ChiCTR2500108695Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in postoperative nausea and vomiting (PONV) comparing Tegileridine group with Hydromorphone group (2 arms). Primary endpoint: Incidence of postoperative nausea and vomiting within 24 hours. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
tegileridinehydromorphone
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2500108695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108695.